TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results

Go back to TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results

TransMedics Group (TMDX) PT Lowered to $28 at Cowen

February 24, 2022 6:56 AM EST

Cowen analyst Joshua Jennings lowered the price target on TransMedics Group (NASDAQ: TMDX) to $28.00 (from $29.00) while maintaining an Outperform rating.

The analyst commented, "TMDX reported 4Q sales of $9.7M, up 27%, vs the $7.5M consensus. It introduced 2022 sales guidance of $49M-$55M, reflecting... More

TransMedics Group (TMDX) Misses Q4 EPS by 4c

February 23, 2022 4:28 PM EST

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of ($0.46), $0.04 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.52 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

... More